AHM Journal editorial office will check each submitted manuscripts for plagiarism including self-plagiarism. Any material quoted from previously published works should be identified as such by corresponding author.

AHM Journal follows the International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations), the Code of Conduct from the Committee on Publication Ethics (COPE), and the EQUATOR Network resource center guidance on good research reporting.

Failure to meet the AHM journal’s ethical and legal policies may result in rejection. Even after publication, any concerns associated with ethics or contents are still subjects to further investigation and action.

Transparency and Disclosure Requirements:

  • Authors and contributors must transparently disclose and describe any use of AI technologies in their submissions.
  • This includes acknowledging AI use in the contributor section and providing detailed descriptions in the methods section.
    • Authors should clearly state:
    • The name of the AI technology used.
    • The rationale behind its usage.
    • The specific tasks the AI technology performed.
  • Authors are encouraged to include summaries of input, output, and the review process of AI-generated content for editorial assessment.

 

Decision Making and Evaluation:

  • AHM Journal will evaluate the reasonableness and consistency of AI usage declarations with its publication policies.
  • Submissions may be rejected or subject to post-publication changes if declarations are inadequate or if AI usage raises concerns.

 

Authorship and Responsibility for AI-Influenced Content:

  • AI technologies will not be recognized as authors of submitted content.
  • Authorship is reserved for accountable human contributors.
  • Authors and contributors are accountable for the accuracy, proper attribution, and originality of content produced or influenced by AI.

 

Detection and Screening:

  • AMH Journal may employ screening tools pre- or post-publication to identify AI-generated content.
  • Such tools may be used systematically or on a case-by-case basis.

 

Peer Review:

  • Reviewers using AI technology during the peer review process must declare its usage.
  • Reviewers should safeguard the confidentiality of unpublished manuscripts.

Research involving human subjects, human material, human tissues or human data should comply with the Declaration of Helsinki. Prior to initializing research, an appropriate approval, licensing or registration must be obtained from an institutional review board (IRB) or equivalent ethics committee.

Relevant documents showing that research received the appropriate approval and was carried out ethically should be provided if requested by the editorial office.

Identifying information of participants should not be shared or disclosed unless strictly necessary for the submission. Written consent for the use of that information should be obtained from participants in that case. Written consent should be obtained for all case reports as well.

AHM Journal follows the recommendations by the International Committee of Medical Journal Editors regarding clinical trial registration.

All clinical trials involving assignment of people to a treatment group should be registered prior to patient enrollment.

Accepted Registries:

Trials must be registered in ClinicalTrials.gov, the primary registry in the United States, or any registry that is a primary register of the World Health Organization International Clinical Trials Registry Platform (ICTRP).

For a full listing of accepted registries, please refer to the World Health Organization International Clinical Trials Registry Platform, Primary Registries.

Some international examples:

The ISRCTN Registry: http://isrctn.org

European Union Clinical Trials Register (EU-CTR) https://www.clinicaltrialsregister.eu/

Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au/

The UMIN Clinical Trials Registry (UMIN-CTR): http://umin.ac.jp/ctr/

The Center for Clinical Trials, Japan Medical Association: http://www.jmacct.med.or.jp/

Chinese Clinical Trial Registry (ChiCTR): http://www.chictr.org/en/

Notation of Registry and IRB Approval:

The clinical trial registry and trial registration number should be noted at the end of the abstract. In addition, the manuscript should note the registry, registration number, and date of registration in the Methods section.

All research involving human subjects should follow the Declaration of Helsinki’s “Ethical Principles for Medical Research Involving Human Subjects” (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).

No manuscript describing investigations carried out in human subjects will be accepted for publication unless the text states that the study was approved by the author’s institutional human investigation committee or research ethics committee and that written informed consent was obtained from all subjects or legal guardians.

A statement regarding Institutional Review Board (IRB) approval and procedures is required and must be clearly stated in the first paragraph of the Methods section.

AHM Journal requires authors to use reporting guidelines.

The EQUATOR Network aims “to improve the quality of scientific publications by promoting transparent and accurate reporting of health research.” If you are unsure which reporting guideline best suits your research, use the EQUATOR Network’s Find the Right Reporting Guideline tool.

Editable checklists for reporting guidelines can be found on the EQUATOR Network site.

The authors are required to submit the completed checklists for the relevant guidelines and flow diagram -if applicable- along with the manuscript.

List of Recommended guidelines:

Randomized trials: CONSORT http://www.consort-statement.org/

Observational studies: STROBE http://www.strobe-statement.org/

Systematic reviews: PRISMA http://www.prisma-statement.org

Clinical practice guidelines: AGREE http://www.agreetrust.org/resource-centre/agree-reporting-checklist/

Animal preclinical studies: ARRIVE http://www.nc3rs.org.uk/arrive-guidelines

Case reports: CARE http://www.care-statement.org

No manuscript describing investigations in animals will be accepted for publication unless a statement in the first paragraph of the Methods section attests that the author’s institutional animal investigation committee approved the study.

The authors are required to comply with the internationally-accepted “3Rs” principles:.

  • Replacement of animals by alternatives wherever possible;
  • Reduction in number of animals used;
  • Refinement of experimental conditions and procedures to minimize the harm to animals.

AHM journal follows the NC3Rs ARRIVE Guidelines (Animal Research: Reporting of In Vivo Experiments). Authors are strongly recommended to use the ARRIVE Guidelines Checklist.

The Editorial Board reserves the right to exercise judgment, which may be more stringent than that imposed by the investigator’s Institutional Review Board, regarding the ethics of a clinical trial involving investigational drugs. Compliance with the following conditions regarding investigational drugs must be stated in the first paragraph of the Methods section.

Studies that involve investigational drugs or devices must meet one of the following three criteria:

  1. The drug or device is approved by the United States Food and Drug Administration (FDA) or equivalent regulatory agency in the country(s) in which the study took place.
  2. The drug or device is not approved for this particular indication, but the drug or device is indeed widely used in this context as evidenced by publication in standard textbooks.
  3. The study is being performed under an Investigational New Drug (IND) application approved by (or waived by) the FDA or equivalent regulatory agency.

In the absence of an approved or waived IND, investigators may be expected to provide upon request the following information as part of the manuscript submission process:

  1. Copies of the Institutional Review Board or Research Ethics Committee application and approval letter.
  2. A copy of the informed consent document that patients were requested to sign.
  3. Discussion as to why the off-label use of the studied drug or device is justified. What unique advantage(s) its use presents over existing ones that might supersede the potential risks.
  4. Reference to and discussion of existing animal and human safety information related to the drug or device.
  5. All claims as to the drug’s safety must be clearly presented in terms of the conditions under which they were studied and accompanied by statistical expressions of potential harm, such as an upper limit of a 95% confidence interval.

The Editorial Board reserves the right to require supplemental information, not limited to that described above, prior to review of or acceptance of the manuscript.